FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105289311> ?p ?o ?g. }

• W2105289311 endingPage "10055" @default.
• W2105289311 startingPage "10039" @default.
• W2105289311 abstract "The clinical efficacy of nucleos(t)ide analogues (NAs) combined with interferon (IFN) therapy vs. NAs monotherapy for chronic hepatitis B (CHB) remains inconclusive. The aim of this meta-analysis was to determine whether the NAs plus IFN regimen offers synergistic efficacy that justifies the cost and burden of such a combination therapy in CHB patients.Related publications covering the period of 1966 to July 2014 were identified through searching MEDLINE, EMBASE, Cochrane library, Chinese Biomedical Literature Database, WANFANG, and CNKI database. A total of 17 studies were enrolled, including 6 in English and 11 in Chinese. Then, we established a final list of studies for the meta-analysis by systematically grading the quality and eligibility of the identified individual studies. We used hepatitis B antigen (HBeAg) loss, HBV-DNA undetectable rate, HBeAg seroconversion, hepatitis B surface antigen (HBsAg) loss, HBsAg seroconversion, and histological score at the end of treatment for efficacy evaluation. A quantitative meta-analysis (Review Manager, Version 5.1.0) was performed to assess the differences between NAs and IFN combination therapy and NAs monotherapy.Our analysis demonstrated that HBeAg loss (RR = 1.73, 95% CI = 1.32-2.26, p < 0.001), HBV-DNA undetectable rate (RR = 1.58, 95% CI = 1.22-2.04, p < 0.001), HBeAg seroconversion (RR = 1.68, 95% CI = 1.36-2.07, p < 0.001), and HBsAg loss (RR = 2.51, 95% CI = 1.32-4.75, p < 0.001) in the combination therapy group were significantly higher than those in the monotherapy group. However, there were no significant differences in HBsAg seroconversion (RR = 4.25, 95% CI = 0.62-29.13, p = 0.14), sustained virological response rates, and biochemical response rates observed between the two groups. The results showed that the combination therapy group had more improved HBV histology than the NAs monotherapy group (RR = 1.14, 95% CI = 0.93-1.39, p = 0.22).NAs and IFN or Peg-IFN combination therapy had a better efficacy in terms of HBeAg loss, HBV-DNA undetectable rate, HBeAg seroconversion, and HBsAg loss, compared to the NA monotherapy group at the end of treatment; however, there was no significant difference in HBsAg seroconversion between the two regimens." @default.
• W2105289311 created "2016-06-24" @default.
• W2105289311 creator A5003799076 @default.
• W2105289311 creator A5012108815 @default.
• W2105289311 creator A5049626085 @default.
• W2105289311 creator A5060423739 @default.
• W2105289311 creator A5066330334 @default.
• W2105289311 date "2015-08-21" @default.
• W2105289311 modified "2023-10-16" @default.
• W2105289311 title "A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis" @default.
• W2105289311 cites W1496655513 @default.
• W2105289311 cites W1504327702 @default.
• W2105289311 cites W1965473659 @default.
• W2105289311 cites W1988570524 @default.
• W2105289311 cites W2008517556 @default.
• W2105289311 cites W2012405019 @default.
• W2105289311 cites W2023704387 @default.
• W2105289311 cites W2026382336 @default.
• W2105289311 cites W2028770751 @default.
• W2105289311 cites W2031317669 @default.
• W2105289311 cites W2032046359 @default.
• W2105289311 cites W2050081098 @default.
• W2105289311 cites W2086082213 @default.
• W2105289311 cites W2101032357 @default.
• W2105289311 cites W2104427317 @default.
• W2105289311 cites W2114785561 @default.
• W2105289311 cites W2141100327 @default.
• W2105289311 cites W2149457301 @default.
• W2105289311 cites W2167744756 @default.
• W2105289311 cites W2169631718 @default.
• W2105289311 cites W2187552837 @default.
• W2105289311 cites W2399431376 @default.
• W2105289311 cites W4211026375 @default.
• W2105289311 cites W861840973 @default.
• W2105289311 doi "https://doi.org/10.3390/ijerph120810039" @default.
• W2105289311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4555327" @default.
• W2105289311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26308024" @default.
• W2105289311 hasPublicationYear "2015" @default.
• W2105289311 type Work @default.
• W2105289311 sameAs 2105289311 @default.
• W2105289311 citedByCount "16" @default.
• W2105289311 countsByYear W21052893112015 @default.
• W2105289311 countsByYear W21052893112016 @default.
• W2105289311 countsByYear W21052893112017 @default.
• W2105289311 countsByYear W21052893112018 @default.
• W2105289311 countsByYear W21052893112019 @default.
• W2105289311 countsByYear W21052893112020 @default.
• W2105289311 countsByYear W21052893112023 @default.
• W2105289311 crossrefType "journal-article" @default.
• W2105289311 hasAuthorship W2105289311A5003799076 @default.
• W2105289311 hasAuthorship W2105289311A5012108815 @default.
• W2105289311 hasAuthorship W2105289311A5049626085 @default.
• W2105289311 hasAuthorship W2105289311A5060423739 @default.
• W2105289311 hasAuthorship W2105289311A5066330334 @default.
• W2105289311 hasBestOaLocation W21052893111 @default.
• W2105289311 hasConcept C126322002 @default.
• W2105289311 hasConcept C203014093 @default.
• W2105289311 hasConcept C2522874641 @default.
• W2105289311 hasConcept C2775940106 @default.
• W2105289311 hasConcept C2776478404 @default.
• W2105289311 hasConcept C2776999253 @default.
• W2105289311 hasConcept C2777382497 @default.
• W2105289311 hasConcept C2777410769 @default.
• W2105289311 hasConcept C2777451964 @default.
• W2105289311 hasConcept C2780593183 @default.
• W2105289311 hasConcept C2781413609 @default.
• W2105289311 hasConcept C71924100 @default.
• W2105289311 hasConcept C90924648 @default.
• W2105289311 hasConcept C95190672 @default.
• W2105289311 hasConceptScore W2105289311C126322002 @default.
• W2105289311 hasConceptScore W2105289311C203014093 @default.
• W2105289311 hasConceptScore W2105289311C2522874641 @default.
• W2105289311 hasConceptScore W2105289311C2775940106 @default.
• W2105289311 hasConceptScore W2105289311C2776478404 @default.
• W2105289311 hasConceptScore W2105289311C2776999253 @default.
• W2105289311 hasConceptScore W2105289311C2777382497 @default.
• W2105289311 hasConceptScore W2105289311C2777410769 @default.
• W2105289311 hasConceptScore W2105289311C2777451964 @default.
• W2105289311 hasConceptScore W2105289311C2780593183 @default.
• W2105289311 hasConceptScore W2105289311C2781413609 @default.
• W2105289311 hasConceptScore W2105289311C71924100 @default.
• W2105289311 hasConceptScore W2105289311C90924648 @default.
• W2105289311 hasConceptScore W2105289311C95190672 @default.
• W2105289311 hasIssue "8" @default.
• W2105289311 hasLocation W21052893111 @default.
• W2105289311 hasLocation W21052893112 @default.
• W2105289311 hasLocation W21052893113 @default.
• W2105289311 hasLocation W21052893114 @default.
• W2105289311 hasOpenAccess W2105289311 @default.
• W2105289311 hasPrimaryLocation W21052893111 @default.
• W2105289311 hasRelatedWork W1982285502 @default.
• W2105289311 hasRelatedWork W1992896253 @default.
• W2105289311 hasRelatedWork W1998000397 @default.
• W2105289311 hasRelatedWork W2028094679 @default.
• W2105289311 hasRelatedWork W2050694322 @default.
• W2105289311 hasRelatedWork W2061734351 @default.
• W2105289311 hasRelatedWork W2064056437 @default.
• W2105289311 hasRelatedWork W2263815274 @default.

• next